Novo CEO on US obesity drug demand: "It was the perfect storm"
At the start of 2022, Novo Nordisk expects to be able to meet the demand for its obesity drug Wegovy in the US. The patient interest was so high, it surprised the CEO.
by benjamin werner christensen, translated by catherine brett
Lars Fruergaard Jørgensen, CEO of Novo Nordisk, does not think anyone can be blamed for the production problems that have affected the company as a result of the launch of Wegovy in the US. His reasoning is that nobody could have predicted the enormously high demand for the drug.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo still expecting EU Wegovy approval around the New Year
For subscribers
